Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Norvasc Generic Substitution Rate Reaches Nearly 77 Percent

This article was originally published in The Pink Sheet Daily

Executive Summary

Rate has increased nearly five fold since amlodipine generics hit the market.

You may also be interested in...



Apotex Launches Generic Norvasc

Launch undercuts Mylan’s claimed 180-day exclusivity for amlodipine.

Apotex Launches Generic Norvasc

Launch undercuts Mylan’s claimed 180-day exclusivity for amlodipine.

Mylan, Pfizer On The Same Side Over FDA Approval Of Pending Norvasc ANDAs

FDA is expected to render a decision on approving additional amlodipine ANDAs on April 11.

Related Content

Topics

UsernamePublicRestriction

Register

LL1126093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel